Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe: author's response

Abstract

In the recent manuscript by Günther G. et al. "Availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe", published in this journal ( 1 Günther G, Guglielmetti L, Kherabi Y, Duarte R, Lange C; Tuberculosis Network European Trials group. Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe. Clin Microbiol Infect. 2024 Mar 13:S1198-743X(24)00121-6. doi: 10.1016/j.cmi.2024.03.009. Epub ahead of print. Google Scholar ) we described the availability of medicines and drug susceptibility testing (DST) for the medicines composing the bedaquiline-pretomanid-linezolid-(moxifloxacin) (BPaL[M]) regimen for individuals affected by multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) in the World Health Organization (WHO) Europe Region as of November 2023, one year after the WHO recommendation for this 6-month duration regimen for the treatment of patients affected by MDR/RR-TB (BPaLM) or pre-extensively drug-resistant tuberculosis (pre-XDR-TB; BPaL) ( 2 World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update Available from: https://www.who.int/publications-detail-redirect/9789240063129 Google Scholar ). Re: 'Availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe' by Lange et al.Clinical Microbiology and InfectionPreviewThe World Health Organization (WHO) recommendation to adopt BPaL(M) for the standard-of-care treatment of multidrug-resistant tuberculosis[1] (MDR-TB, resistance to at least isoniazid and rifampicin) has sparked hope for patients who would otherwise undergo a complex and long therapy, often associated with severe and long-lasting side effects [2]. The BPaL(M) regimen includes bedaquiline in association with pretomanid, a nitroimidazole compound, and two drugs belonging to the WHO group A compounds, linezolid, and moxifloxacin. Full-Text PDF Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in EuropeClinical Microbiology and InfectionPreviewMultidrug-resistant/rifampicin-resistant tuberculosis is a major obstacle to successful tuberculosis control. The recommendation by the WHO to use bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) for 6 months, based on results of two trials with high efficacy and low toxicity, has revolutionized treatment options. Full-Text PDF